Threshold Pharmaceuticals: Clinical Trials

4 trials sponsored by Threshold Pharmaceuticals, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 terminated. 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 34Completed 3, Terminated 1

Follow Threshold Pharmaceuticals: new trials by email

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
TH-302, Gemcitabine, Placebo (5 percent dextrose - D5W) - Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Phase 3CompletedImmunoGenesis6932012-12-012025-05-11
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
TH-302 in Combination with Doxorubicin, Doxorubicin - Soft Tissue Sarcoma
Phase 3CompletedThreshold Pharmaceuticals6402011-09-012016-06-02
Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Lonidamine - Benign Prostatic Hyperplasia, Enlarged Prostate
Phase 3TerminatedThreshold Pharmaceuticals4802005-06-012009-04-29
Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer
Glufosfamide - Pancreatic Cancer
Phase 3CompletedThreshold Pharmaceuticals3002004-09-012009-04-30

Conditions studied

Neoplasm Metastasis (2)  ·  Pancreatic Neoplasms (2)  ·  Neoplasms (1)  ·  Prostatic Hyperplasia (1)  ·  Sarcoma (1)

Interventions

TH 302 (2)  ·  Doxorubicin (1)  ·  Gemcitabine (1)  ·  beta-D-glucosylisophosphoramide mustard (1)  ·  lonidamine (1)

Countries

Germany (3)  ·  Hungary (3)  ·  United States (3)  ·  Italy (2)  ·  Poland (2)  ·  Russia (2)  ·  Argentina (1)  ·  Austria (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Bulgaria (1)  ·  Canada (1)  ·  Czechia (1)  ·  Denmark (1)  ·  France (1)

Top investigators

Antonio Gualberto, MD, PhD (1)  ·  Peter Alken, MD (1)  ·  William Tap, MD (1)

Results publications

PMID 25185097, PMID 25512461, PMID 28651927